Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
EpiVax Therapeutics
Providence, Rhode Island, United Statesepivaxtx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
EpiVax Therapeutics is developing personalized neoantigen vaccines for cancer and a T cell epitope‑based peptide vaccine for COVID‑19; its COVID‑19 candidate EPV-CoV-19 has completed IND‑enabling preclinical studies with in vitro human T cell and in vivo HLA‑transgenic mouse immunogenicity data, and cancer programs are currently at preclinical and vaccine-design capacity stages.[4][5][6]
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccinePeptidesmRNA-based drugs
- Industry
- Biotech
02
Partnerships
GreenLight Biosciences[6]
Beyond the preview
Go deeper on EpiVax Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EpiVax Therapeutics.